The place of molecularly targeted drugs in the treatment of lung adenocarcinoma is becoming increasingly evident, but in practice, far less attention has been paid to EGFR mutation detection. Since the use of drugs targeting EGFR mutations in patients without EGFR mutations is not only not beneficial, but harmful. A few days ago, when I attended a drug clinical trial seminar, a veteran surgical oncologist thought that EGFR mutation testing was not very meaningful. After explaining to him, he still thought that until the accuracy rate of EGFR mutation testing results reached 100%, all targeted therapeutic drugs could be tried. Recently, in my work, I came across patients with lung adenocarcinoma who were transferred from the following hospitals, some of whom had EGFR wild type were taking oral troche, and some even had EGFR exon 20 mutation patients taking oral troche, but more of them were not tested for EGFR mutation. In practice, we have encountered many patients who have progressed after chemotherapy, but their general condition is fine. The phenomenon of not paying attention to EGFR mutation testing is very common in China. In 2013, CSCO Xiamen, Prof. Wu Yilong’s survey report showed that only 50% of patients in first-line treatment were able to receive EGF mutation testing, and the testing rate in second-line treatment was even lower (this may be related to the lack of guideline recommendation). In addition, Prof. Lu Shun mentioned that in Japan, the delivery rate of EGFR in lung cancer patients is 80%, while in China it is only 20% as of 2013.